| Literature DB >> 28083704 |
Sajad Varmazyar1, Sayed Mahdi Marashi1, Zabihollah Shoja2, Maria Lina Tornesello3, Franco M Buonaguro3, Shohreh Shahmahmoodi1,4, Zahra Safaie-Naraghi5, Somayeh Jalilvand6.
Abstract
A single-nucleotide polymorphism (SNP) in the promoter region of MDM2 (SNP309T>G, rs2279744) has been shown to increase the expression of the MDM2 protein in various cancer types. However, only one study has analyzed the role of the MDM2 polymorphism in the development of Kaposi's sarcoma (KS). The association of MDM2 SNP309 with classic KS risk was evaluated in 79 Iranian patients with classic KS and 123 healthy controls. The MDM2 SNP309 was genotyped using PCR and restriction fragment length polymorphism methods. No significant correlation was found between the SNP309 polymorphism in MDM2 promoter and classic KS risk. There was no significant correlation between gender and disease stage. However, a significant association was found between SNP309 GG genotype and younger age (≤50 years) (odds ratio 9.5, 95% confidence intervals 1.5-60, p = 0.03). Our findings support no major role for the MDM2 SNP309 in KS development although it might influence the clinical outcome of KS in younger patients.Entities:
Keywords: Kaposi’s sarcoma; MDM2; Risk factor; Single-nucleotide polymorphism
Mesh：
Substances：
Year: 2017 PMID： 28083704 DOI： 10.1007/s00430-016-0491-9
Source DB: PubMed Journal: Med Microbiol Immunol ISSN： 0300-8584 Impact factor: 3.402